Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, has announced the launch of its 4RISE™ high-throughput wet-lab validation services for AI-designed protein binders. The services are designed to bridge the gap between computational protein design and experimental validation, offering 3-hour cell-free expression, AI-ready binding data in as little as 3 days, and real-time API access to structured target-binding data.
The announcement, made via NEWMEDIAWIRE, highlights the growing need for reliable wet-lab evidence as AI-driven protein design accelerates the discovery of novel protein binders. While computational tools can generate candidate molecules quickly, experimental validation remains essential to determine whether designs translate into meaningful target interactions.
4RISE™ combines rapid experimental turnaround, scalable screening workflows, and structured data delivery to support continuous design-test-learn cycles. The services are built on Sino Biological’s XPressMAX™ Cell-Free Protein Synthesis (CFPS) platform, which enables recombinant protein synthesis in just 3 hours with expression success rates exceeding 99% in established workflows. The platform supports the synthesis of miniproteins, VHHs, scFvs, Fabs, enzymes, and cytokines, allowing researchers to test AI-designed candidates faster.
Using Carterra high-throughput SPR, Biacore SPR, and Octet BLI, 4RISE™ delivers high-throughput binding screening, kinetic analysis, and affinity determination. Combined with CFPS, the workflow provides sequence-to-AI-ready binding data in as little as 3 days, with structured data accessible in real time via API for downstream research and analysis.
The services offer four rapid screening options: Rapid Hit Discovery for binding-positive miniproteins and VHHs through crude-supernatant screening; Comparative Binder Screening for purified candidates under standardized conditions; Affinity & Kinetic Characterization for quantitative binding insights; and Specialized Binder Expression & Validation for diverse binder formats. Beyond binding, 4RISE™ provides 20+ developability assays, 1,000+ protein bioactivity assays, and 10+ cell-based functional assays.
“AI-designed molecules need reliable wet-lab experimental evidence to demonstrate their potential,” said Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc. “Our integrated capabilities provide the high-quality data researchers need to evaluate candidates quickly, shorten design cycles, and turn promising discoveries into real-world applications.”
Sino Biological works with AI companies on wet-lab validation for AI-designed antibody discovery, de novo binder design, and computational protein engineering. 4RISE™ wet-lab validation has supported studies published in Science, Nature Communications, Scientific Reports, and other high-impact journals. The company serves researchers in more than 90 countries through its recombinant proteins, antibodies, and customized research services.
For AI-focused life sciences researchers, the launch means faster iteration cycles and higher-confidence candidate selection, potentially reducing the time and cost of early drug discovery. The ability to obtain structured binding data in days rather than weeks could significantly accelerate AI-driven discovery pipelines. More information is available at www.sinobiological.com, and researchers can explore 4RISE™ High-Throughput Wet-Lab Validation Services Now!.
